4.3 Article

Twitter in urology and other surgical specialties at global conferences

Journal

ANZ JOURNAL OF SURGERY
Volume 86, Issue 4, Pages 224-227

Publisher

WILEY-BLACKWELL
DOI: 10.1111/ans.13393

Keywords

clinical conference; social media; surgery; urology; twitter messaging

Categories

Ask authors/readers for more resources

Background: Over recent years, Twitter has demonstrated an expanding role in scientific discussion, surgical news and conferences. This study evaluates the role of Twitter in urological conferences, with comparison to other surgical specialties. Methods: A retrospective analysis of Twitter metrics during the two largest recent English-speaking conferences for each surgical specialty was performed. Using www.symplur.com, all 'tweets' under the official conference hashtag from 0000 hour the first day to 24.00 hour the final day were assessed. The number of impressions, 'tweeters' and rates of 'tweeting' were analysed. Results: Nine of 18 conferences examined had official hashtags registered with Symplur Healthcare Hashtags. Plastic and urological surgery had both major conferences registered. Only one of two conferences for each cardiothoracic, general, orthopaedic, otolaryngology and paediatric was registered. Both major neurosurgical and vascular conferences were unregistered. Urological conferences were associated with significantly more Twitter activity than non-urological surgical conferences in all parameters, with greater than triple the number of impressions, tweets and 'tweeters'. Urological surgical conferences were associated with 337% more tweets and 164% more impressions per conference day, than non-urological surgical conferences. Conclusion: Twitter has been used to supplement surgical conferences. In this regard, the urological community leads the way compared to the remainder of surgical specialty communities.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Urology & Nephrology

Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer

Amer Amin, Alexandar Blazevski, James Thompson, Matthijs J. Scheltema, Michael S. Hofman, Declan Murphy, Nathan Lawrentschuk, Niranjan Sathianathen, Jada Kapoor, Henry H. Woo, Venu Chalasani, Krishan Rasiah, Pim J. van Leeuwen, Reuben Tang, Thomas Cusick, Phillip Stricker, Louise Emmett

BJU INTERNATIONAL (2020)

Article Oncology

TREXIT 2020: why the time to abandon transrectal prostate biopsy starts now

Jeremy Grummet, Michael A. Gorin, Rick Popert, Tim O'Brien, Alastair D. Lamb, Boris Hadaschik, Jan Philipp Radtke, Florian Wagenlehner, Eduard Baco, Caroline M. Moore, Mark Emberton, Arvin K. George, John W. Davis, Richard J. Szabo, Roger Buckley, Andrew Loblaw, Matthew Allaway, Christof Kastner, Erik Briers, Peter L. Royce, Mark Frydenberg, Declan G. Murphy, Henry H. Woo

PROSTATE CANCER AND PROSTATIC DISEASES (2020)

Review Oncology

Mainstream consent programs for genetic counseling in cancer patients: A systematic review

Tahlia Scheinberg, Alison Young, Henry Woo, Annabel Goodwin, Kate L. Mahon, Lisa G. Horvath

Summary: As the demand for germline genetic testing for cancer patients increases, novel methods of genetic counseling are required. Mainstream pathways, conducted by medical oncologists and nurses, have been found acceptable and feasible, with a focus on breast and ovarian cancer patients undergoing BRCA testing. Further research is needed to evaluate the mainstream pathway for men with prostate cancer.

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2021)

Editorial Material Medicine, General & Internal

Clinically significant localised prostate cancer: deciding what will provide the best clinical outcomes

Henry H. Woo, Amy Teh

MEDICAL JOURNAL OF AUSTRALIA (2021)

Letter Medicine, General & Internal

Differences in treatment choices for localised prostate cancer diagnosed in private and public health services

Henry H. Woo, Declan G. Murphy

MEDICAL JOURNAL OF AUSTRALIA (2021)

Article Oncology

The UroLift implant: mechanism behind rapid and durable relief from prostatic obstruction

Claus G. Roehrborn, Peter T. Chin, Henry H. Woo

Summary: The UroLift implant causes tissue compression, focal ischemia, local atrophy, and minimal-mild chronic inflammation, ultimately remodeling tissue to widen the prostatic urethra. Studies show no impact on systemic tissue, proving the device is benign, biocompatible, and provides long-term durability.

PROSTATE CANCER AND PROSTATIC DISEASES (2022)

Correction Oncology

The UroLift implant: mechanism behind rapid and durable relief from prostatic obstruction (Aug, 10.1038/s41391-021-00434-0, 2021)

Claus G. Roehrborn, Peter T. Chin, Henry H. Woo

PROSTATE CANCER AND PROSTATIC DISEASES (2022)

Article Oncology

The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)

Henry H. Woo, Chi-Ping Huang, William J. Huang, Yi-Huei Chang, Chi-Shun Lien, Archil Chkhotua, Dean S. Elterman

Summary: The study aims to demonstrate the safety and feasibility of the Urocross Expander System for treating patients with BPH/LUTS. The results show improvements in clinical parameters and no severe complications in patients. This provides evidence for further evaluation of the efficacy of the procedure.

PROSTATE CANCER AND PROSTATIC DISEASES (2022)

Review Medicine, General & Internal

PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer

Alexander D. Combes, Catalina A. Palma, Ross Calopedos, Lingfeng Wen, Henry Woo, Michael Fulham, Scott Leslie

Summary: This paper reviews the role of PSMA PET-CT in prostate cancer, including its improvement in the detection of loco-regional and metastatic disease, primary diagnosis and staging, detection of biochemical recurrence after treatment, and metastasis-directed therapy.

DIAGNOSTICS (2022)

Article Urology & Nephrology

Australian surgical revision rate for benign prostatic obstruction

Anika Jain, Anthony-Joe Nassour, Hadia Khannani, Michael P. Wines, Venu Chalasani, Phillip Katelaris, Philip Bergersen, James L. Symons, Sris Baskaranathan, Henry Woo

Summary: This study evaluated the rate of revision surgery for commonly performed procedures for benign prostatic hyperplasia (BPH) using real-world data from Medicare Australia. The results showed that transurethral resection of the prostate (TURP) and photoselective vaporization of the prostate (PVP) had similar durability after 5 years of follow-up.

BJU INTERNATIONAL (2023)

Article Oncology

Retreatment rates and postprocedural complications are higher than expected after BPH surgeries: a US healthcare claims and utilization study

Steve Kaplan, Ronald P. Kaufman Jr, Thomas Mueller, Dean Elterman, Bilal Chughtai, Daniel Rukstalis, Henry Woo, Claus Roehrborn

Summary: This study compares and analyzes different treatment options for BPH surgery using US healthcare claims data. The results suggest that within one year of BPH surgery, approximately 1 in 20 patients may require retreatment, and for some technologies, as many as 1 in 4 patients may require treatment for complications.

PROSTATE CANCER AND PROSTATIC DISEASES (2023)

Review Andrology

Alfuzosin and Its Effect on Ejaculatory Dysfunction: A Systematic Review

Haywood E. L. Yeung, Stephen J. Sena, Ross J. Calopedos, Henry H. Woo

Summary: This study evaluated the impact of alfuzosin on ejaculatory function and found that alfuzosin may improve ejaculatory function in addition to LUTS. It should be considered in sexually active men or those complaining of deteriorating ejaculation.

WORLD JOURNAL OF MENS HEALTH (2021)

Meeting Abstract Urology & Nephrology

FIRST-IN-HUMAN CLINICAL EXPERIENCE WITH THE XFLO EXPANDER SYSTEM TO TREAT LOWER URINARY TRACT SYMPTOMS SECONDARY TO BENIGN PROSTATIC HYPERPLASIA

Henry Woo, Chi-Ping Huang, Chi-Shun Lien, Archil Chkhotua

JOURNAL OF UROLOGY (2020)

Meeting Abstract Urology & Nephrology

Robotic retroperitoneal lymph node dissection: an initial single centre experience

H. Fernando, A. Goolam, S. Leslie, R. Downey, H. Woo, P. Ferguson, G. Watson, N. Ahmadi

BJU INTERNATIONAL (2019)

No Data Available